Roche’s eye implant may reduce treatment time for vision loss in older people – clinical daily news



The Food and Drug Administration has approved an eye implant that could reduce the need for treatment for vision loss from one month to two times a year for some elderly people, drugmaker Roche said.

Susvimo ​​involves an implanted port that allows the continuous administration of the drug ranibizumab from Roche directly into the eye to treat neovascular or “wet” age-related macular degeneration (nAMD).

The disease can lead to blindness, and the current standard of care may require a visit to a doctor every four to six weeks for therapeutic injections that slow or stop vision loss. Missed appointments can lead to disease progression. The port’s new delivery system, on the other hand, is implanted through a tiny incision in the eye, potentially reducing those clinic visits to just twice a year and improving compliance by allowing refills, according to the drug’s developers. .

In the United States, approximately 8 million adults aged 50 and over suffer from age-related macular degeneration, an incurable disease. The advanced stage causes blindness in 1.75 million Americans, and prompt treatment is crucial.

Susvimo ​​offers the first alternative to nAMD treatment to be approved in 15 years, Roche said in a declaration.



Comments are closed.